The company’s order book as on March 31, 2020, stood at Rs 7,462 crore (4x of FY20 revenue), which is likely to be executed over the next two and a half years. The total order inflow so far in FY21 stands at Rs 290 crore. This inflow, combined with a healthy order book, provides strong revenue visibility.

A few other companies have also launched Remdesivir recently, which includes names like Cipla at a price of Rs 4,000 and Jubilant Life Sciences at Rs 4,700. Further, Dr Reddy is also expecting to launch Remdesivir in August 2020 and it has received a voluntary licence from Gilead Sciences to manufacture and distribute the said drug.

With the lower output of manufacturing, mining, and power generation, India's factory output, measured on the basis of Index of Industrial Production (IIP), declined by 16.6 per cent in June 2020.

The company has received USFDA nod for the additional four variants to market them in the United States. Earlier, the company had received USFDA approval for one variant of male contraceptives.

Major companies in today’s trading session are trading in the green, which includes, BEL- up by 15 per cent, Bharat Dynamics- up by 11 per cent, Solar Industries India- up by 8 per cent, Hindustan Aeronautics- up by 10 per cent, Bharat Forge- up by 7 per cent and BEML- up by 6 per cent.

The promoters have released 27 lakh equity shares, with reference to the earlier announcements. The promoters have informed the company that they have repaid Rs 58.09 crore and now the outstanding amount is Rs 5.91 crore.

During July 2020, the company has managed to achieve a healthy performance amid the current uncertain situation due to COVID-19. The company’s production and sales volume stood at 2.19 MT and 2.57 MT, showing growth by 13 per cent and 7 per cent, respectively on a YoY basis.

The company’s order book as on March 31, 2020, stood at over Rs 20,503 crore. Its order book mix comprises of T&D-54 per cent, Railways-29 per cent, Civil-13 per cent, Cables-2 per cent and others- 1 per cent.

The company is going to market this product under the brand name ‘Jubi-R’ in India. The company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India through its distribution network.

Zydus Cadila, a part of Cadila Healthcare, informed the bourses during the weekend that it has received tentative approval from United States Food and Drug Administration (USFDA) for Carbidopa and Levodopa extended-release capsules.